Skip to main content

The RheumNow Week in Review – 13 January 2017

Dr. Jack Cush reviews highlights from this past week on RheumNow.com:

  1. ARTIS RA registry shows those initiating a TNFi within 5 yrs of onset double their odds of returning to work in 3 yrs https://t.co/WytSlSYRj1
  2. ARTIS & DANBIO registries: 8703 SpA (AS, PsA) patients treated with TNFI: they do NOT have an increase risk of cancer overall; nor the 6 most common types CA http://buff.ly/2icvD9O
  3. Hepatosplenic T cell lymphoma: review shows this to be a very rare event with TNFi; but is more common in IBD pts (younger), receiving thiopurines. http://buff.ly/2jn7Bqm
  4. Biosimilar Inflectra priced at only a 15% discount; CMS issues payment and claims processing information https://t.co/lCwn198PAN
  5. There is no interaction between low dose weekly MTX and NSAIDs, PCNs or PPIs. https://t.co/h4JeLoSbEg
  6. FDA reviewing a new drug application (NDA) for the new combo drug: allopurinol + lesinurad (Ironwood Pharm) to Rx hyperuricemia and uncontrolled gout https://t.co/e95R8TlXuv
  7. Meta-analysis of 1069 knee OA patients- intraarticular Platelet Rich Plasma (vs HA, NS) shows significantly better WOMAC pain/function scores. @12mo https://t.co/LBJt2SbZXO,
  8. Chronic PPI use associated with 74% more C difficile infections & 2.5-fold increased risk of recurrent C difficile with chronic PPI https://t.co/W1mLbPEPYP
  9. 13% of US African Americans have diabetes; but AA are seldom included in diabetes clinical trials. Whatsupwiththat? https://t.co/GYgXnAcyzb
  10. Total knee vs hemiarthroplasty show equal outcomes;more complications with bilateral total knee replacements (pt selection is critical to the success of hemiarthroplasty) https://t.co/D8OXH8VnTA
  11. 94 pts with MTX pancytopenia in elderly; 24% mortality; risk factors include age>65, sepsis + hypoalbuminemia https://t.co/7p99v9bt3g
  12. Multiple Comorbidity Risks with Giant Cell Arteritis
  13. Do Exercise ‘Weekend Warriors’ Lower Their Risk of Death? 
  14. The IL-6 Wars 
  15. DMARDs Under Study for Secondary Prevention of Cardiovascular Events
     

 

ADD THE FIRST COMMENT

If you are a health practitioner, you may to comment.

Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.

Disclosures
The author has no conflicts of interest to disclose related to this subject
The author has received compensation as an advisor or consultant on this subject